```json
{
"content": [
{
"type": "paragraph",
"content": "North America (39% share) remains the largest Radiopharmaceutical for Nuclear Medicine market, underpinned by the highest global PET/CT installed base, CMS reimbursement for F-18, Ga-68, Lu-177 agents, and aggressive hospital investments in cyclotron and radiochemistry GMP suites. Europe (30% share) follows, with the new EANM "Theragnostics" policy package and €1.2bn EU Resilience4Health fund accelerating PET tracer standardization; Germany and France dominate demand for Lu-177 PSMA and Y-90 microspheres."
},
{
"type": "paragraph",
"content": "Asia Pacific (22% share) is the fastest-growing region, posting 14% CAGR. Drivers include Japan’s universal coverage for PET myocardial perfusion, China’s NMPA fast-track designation for domestic Ga-68 generator production, and India’s 30m annual oncology screenings creating a vast theragnostic pipeline. Localized cyclotron PPPs cut import dependence and shorten half-life logistics."
},
{
"type": "paragraph",
"content": "Latin America (6% share) sees Radiopharmaceutical for Nuclear Medicine market growth propelled by Brazil’s SUS inclusion of Lu-177 DOTATATE, Chile’s public-private cyclotron consortium, and rising prostate-cancer incidence (up 9% p.a.). Middle East & Africa (3% share) benefits from UAE mandatory health coverage for PET CT scans, Saudi Vision 2030 hospital PPPs, and South Africa’s new nuclear medicine hub at Pelindaba; however, skills migration and isotope import tariffs temper the regional forecast."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 39 },
{ "name": "Europe", "value": 30 },
{ "name": "Asia Pacific", "value": 22 },
{ "name": "Latin America", "value": 6 },
{ "name": "Middle East & Africa", "value": 3 }
]
}
}
```
